Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | SCD | O00767 | 4/20 | 0.48 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 3/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | THRB | P10828 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 3/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 4/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | TP53 | P04637 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | SMO | Q99835 | 1/20 | 0.41 |
| ▸ | OGA | O60502 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1744169 | 0.95 | LMNA (0.53) | LMNASCDCNR2RAB9AMAPT | |
| SCHEMBL13654324 | 0.86 | LMNA (0.49) | LMNASCDCNR2RAB9AMAPT | |
| SCHEMBL13177706 | 0.84 | LMNA (0.50) | LMNASCDCNR2RAB9AMAPT | |
| SCHEMBL13451195 | 0.83 | SCD (0.46) | LMNASCDRAB9AMAPTNPC1 | |
| SCHEMBL3150420 | 0.82 | MAPT (0.50) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL1744869 | 0.82 | KDM4E (0.54) | RAB9AMAPTNPC1SMN1; SMN2MEN1 | |
| SCHEMBL3972252 | 0.82 | MAPT (0.50) | LMNACNR2RAB9AMAPTNPC1 | |
| SCHEMBL3184753 | 0.82 | NPC1 (0.59) | CNR2RAB9AMAPTNPC1SMN1; SMN2 | |
| SCHEMBL1743052 | 0.81 | HRH3 (0.47) | MAPTSMN1; SMN2HRH3KDM4ESMO | |
| SCHEMBL1742391 | 0.80 | HRH3 (0.54) | MAPTSMN1; SMN2HRH3KDM4ESMO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | LMNA 4775/4885SCD 3788/4885CNR2 26/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | LMNA 4775/4885SCD 3788/4885CNR2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.